Sandoz Confirms Launch Of Humira Rival In Canada
Introduction Of Hyrimoz Comes As Other Adalimumab Biosimilars Expected
Sandoz has confirmed the launch of its Hyrimoz biosimilar rival to Humira in Canada, with other biosimilars firms having also set their sights on a mid-February launch.
You may also be interested in...
Samsung Bioepis has confirmed launch plans for its citrate-free, high-concentration Hadlima (adalimumab) biosimilar after it was waved through the Canadian healthcare regulator.
The first biosimilar approval stemming from Alvotech’s collaboration with JAMP Pharma in Canada has arrived, with the firms’ Simlandi (adalimumab) biosimilar version of AbbVie’s higher-strength Humira. Celltrion has also announced an approval from Health Canada.
Sandoz Canada has taken another “important step as we pursue our ambition to become the leading biosimilars and generics company” with the launch of biosimilar enoxaparin.